Increased susceptibility to erythrocyte C5b-9 deposition and complement-mediated lysis in chronic renal failure Jonathan Himmelfarb, Ellen Mcmonagle,

Slides:

Advertisements

Similar presentations

Renal Stress Testing in the Assessment of Kidney Disease Lakhmir S. Chawla, Claudio Ronco Kidney International Reports Volume 1, Issue 1, Pages (May.

Advertisements

Volume 63, Issue 4, Pages (April 2003)

Kamyar Kalantar-Zadeh Kidney International

Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody– associated vasculitis Shen-Ju Gou, Jun Yuan, Min Chen, Feng Yu,

Volume 65, Issue 6, Pages (June 2004)

Renal manifestations in Fabry disease and therapeutic options

End-stage renal disease in developing countries

The case ∣ A young woman with abdominal discomfort and a mass

Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody– associated vasculitis Shen-Ju Gou, Jun Yuan, Min Chen, Feng Yu,

The Case ∣ Ascites with oliguric acute renal failure

Continuous renal replacement therapy in the critically ill patient

Progression of renal failure and hypertensive nephrosclerosis

Section 5: Dialysis Interventions for Treatment of AKI

Burden of chronic kidney disease: North Africa

Smoking and cardiovascular outcomes in dialysis patients: The United States Renal Data System Wave 2 Study1,2 Robert N. Foley, Charles A. Herzog, Allan.

Volume 58, Issue 1, Pages (July 2000)

Kamyar Kalantar-Zadeh Kidney International

Volume 61, Issue 1, Pages (January 2002)

Volume 63, Issue 2, Pages (February 2003)

Comorbidity and confounding in end-stage renal disease

Early mortality in dialysis and adequacy of predialysis renal care: the picture is more complex than we thought Nicolas Rognant, Maurice Laville Kidney.

The importance of increased dialysis and anemia management for infant survival in pregnant women on hemodialysis Sai Subhodhini Reddy, Jean L. Holley

Volume 74, Issue 3, Pages (August 2008)

Volume 70, Issue 11, Pages (December 2006)

Joseph W. Eschbach, John W. Adamson Kidney International

Volume 67, Issue 2, Pages (February 2005)

Prevention of renal failure: The Malaysian experience

Volume 70, Issue 12, Pages (December 2006)

Ferruh Artunc, Friedhelm Hildebrandt, Kerstin Amann

Fructose intake as a risk factor for kidney stone disease

Volume 65, Issue 6, Pages (June 2004)

Volume 84, Issue 4, Pages (October 2013)

Volume 76, Issue 6, Pages (September 2009)

The Case | Idiopathic hypocomplementemic interstitial nephritis

The third World Kidney Day: Looking back and thinking forward

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Nephrology in Latin America, with special emphasis on Brazil

Nephrology Crossword: Peritoneal Dialysis

Cardiovascular disease in pediatric chronic dialysis patients

The global challenge of chronic kidney disease

Nephrology Crossword: Glomerulonephritis

Volume 71, Issue 4, Pages (February 2007)

Volume 65, Issue 3, Pages (March 2004)

Does rituximab help in HLA desensitization for kidney transplantation?

Volume 73, Issue 9, Pages (May 2008)

Volume 82, Issue 9, Pages (November 2012)

Opportunities for a chronic disease outreach program in China

Peritoneal dialysis in Mexico

Wei-Teing Chen, Horng-Chin Yan, Fu-Chiu Yu Kidney International

Organ transplantation goes to the movies

Volume 63, Issue 2, Pages (February 2003)

Does equal care give equal outcomes?

Volume 69, Issue 1, Pages (January 2006)

The Danish Renal Biopsy Register

Chyluria presenting as milky urine and nephrotic-range proteinuria

Charles A. Herzog Kidney International

Is complement a target for therapy in renal disease?

Volume 64, Issue 3, Pages (September 2003)

T cells and T-cell receptors in acute renal failure

Volume 70, Issue 10, Pages (November 2006)

The International Pediatric Peritonitis Registry: Starting to walk

Hemodialysis access failure: a call to action—revisited

D.J. Askenazi, D.I. Feig, N.M. Graham, S. Hui-Stickle, S.L. Goldstein

Volume 56, Issue 6, Pages (December 1999)

Volume 60, Issue 6, Pages (December 2001)

Peter Stenvinkel, Olof Heimbürger, Catherine H. Tuck, Lars Berglund

Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies Lei-Shi Li, Zhi-Hong Liu Kidney International

Alex B. Magil, Kathryn Tinckam Kidney International

Tissue proteomics: a new investigative tool for renal biopsy analysis

Presentation transcript:

Increased susceptibility to erythrocyte C5b-9 deposition and complement-mediated lysis in chronic renal failure Jonathan Himmelfarb, Ellen Mcmonagle, Diane Holbrook, Raymond Hakim Kidney International Volume 55, Issue 2, Pages 659-666 (February 1999) DOI: 10.1046/j.1523-1755.1999.00277.x Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 1 Identification of C5b-9 deposition on intact erythrocytes by flow cytometry. #P < 0.01 vs. normal controls; *P < 0.01 vs. samples without the addition of cobra venom factor (CVF). Symbols are: (□) no CVF; (▧) CVF. Kidney International 1999 55, 659-666DOI: (10.1046/j.1523-1755.1999.00277.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 2 Electron micrographs demonstrating erythrocyte membrane blebbing and ghost formation after addition of cobra venom factor. Panel B represents further magnification of A. Kidney International 1999 55, 659-666DOI: (10.1046/j.1523-1755.1999.00277.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 3 Identification of C5b-9 deposition on erythrocyte ghosts using flow cytometry. #P < 0.01 vs. normal volunteers; *P < 0.01 vs. samples without the addition of cobra venom factor. Symbols are: (□) no CVF; (▧) CVF. Kidney International 1999 55, 659-666DOI: (10.1046/j.1523-1755.1999.00277.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 4 Identification of C5b-9 deposition on erythrocyte ghosts by ELISA. #P < 0.01 vs. normal volunteers; *P < 0.01 vs. samples without cobra venom factor. Symbols are: (□) no CVF; (▧) CVF. Kidney International 1999 55, 659-666DOI: (10.1046/j.1523-1755.1999.00277.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 5 Erythrocyte surface protectin (CD59) and decay accelerating factor (CD55), measured by flow cytometry. Symbols are: (□) no dialysis; (▧) dialysis. Kidney International 1999 55, 659-666DOI: (10.1046/j.1523-1755.1999.00277.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 6 SC5b-9 levels measured by ELISA after cobra venom factor stimulation. *P < 0.00 vs. normal volunteers. Kidney International 1999 55, 659-666DOI: (10.1046/j.1523-1755.1999.00277.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 7 Intradialytic increases in LDH levels. *P < 0.05 compared with predialysis. Symbols are: (▪) 15min; (▧) 60min; (□). Kidney International 1999 55, 659-666DOI: (10.1046/j.1523-1755.1999.00277.x) Copyright © 1999 International Society of Nephrology Terms and Conditions